BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 18, 2002
View Archived Issues
Cell therapy as a treatment for myocardial infarction and heart failure
Read More
Endo updates investors at healthcare conference
Read More
Squalamine enters clinical trials for fibrodysplasia ossificans progressiva
Read More
Generex's buccal morphine demonstrates proof of concept in phase I study
Read More
AtheroGenics aggressively developing lead compound
Read More
ProSorb formulation of pain medication enters pivotal trials
Read More
Activity and adequate safety demonstrated in phase II trial of Onconase in malignant mesothelioma
Read More
Orally and topically administered C5a antagonist effective in dermal immunoinflammatory reaction
Read More
Potent and selective ETA receptor antagonist potently lowers blood pressure in rats
Read More
Efficacy of novel mucosal vaccine delivery system described by RxKinetix in recent article
Read More
Corixa and Beaufour Ipsen collaborate on AnergiX.MG technology for myasthenia gravis
Read More
Oxford GlycoSciences, Medarex and Genmab in new initiative against cancer
Read More
Enbrel approved for treatment of psoriatic arthritis
Read More
Phase 2 Discovery to develop LY-156735 for sleep disorders
Read More
Risedronate receives approval in Japan
Read More
Alizyme's mucositis drug ATL-104 proves safe and well tolerated in phase Ia trial
Read More
Board recommends continuing phase III trial of Actimmune for IPF
Read More
Alliance looks to resume phase III program for Oxygent
Read More
Palonosetron completes phase III trials for CINV
Read More
New NK1 receptor antagonists described recently by Roche
Read More
Preparation and use of new thiourea NPY Y1 antagonists for eating disorders
Read More
Anticoagulants derived from phenylglycine at Roche
Read More
European scientists design triterpenoids which inhibit CDKs
Read More
MMP inhibitors and potential uses thereof reported by Aventis
Read More
Vertex researchers synthesize series of caspase inhibitors
Read More